WallStSmart

Merck & Company Inc (MRK)vsTalkspace Inc (TALK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 27320% more annual revenue ($67.38B vs $245.73M). MRK leads profitability with a 3.6% profit margin vs 0.1%. MRK earns a higher WallStSmart Score of 44/100 (D).

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TALK

Hold

40

out of 100

Grade: D

Growth: 8.7Profit: 3.5Value: 5.0Quality: 7.8
Piotroski: 4/9Altman Z: 3.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-72.9%)

Margin of Safety

-72.9%

Fair Value

$84.87

Current Price

$146.99

$62.12 premium

UndervaluedFair: $84.87Overvalued

Intrinsic value data unavailable for TALK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

TALK2 strengths · Avg: 10.0/10
EPS GrowthGrowth
181.1%10/10

Earnings expanding 181.1% YoY

Altman Z-ScoreHealth
3.9510/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

TALK4 concerns · Avg: 2.8/10
Market CapQuality
$868.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.0%3/10

ROE of 1.0% — below average capital efficiency

Profit MarginProfitability
0.1%3/10

0.1% margin — thin

Free Cash FlowQuality
$-7.62M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TALK

The strongest argument for TALK centers on EPS Growth, Altman Z-Score. Revenue growth of 13.6% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : TALK

The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

TALK carries more volatility with a beta of 1.12 — expect wider price swings.

TALK is growing revenue faster at 13.6% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (44/100 vs 40/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Talkspace Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?